{
  "id": "5c663afe7c78d69471000013",
  "type": "yesno",
  "question": "Is pacritinib effective for treatment of myelofibrosis?",
  "ideal_answer": "Yes.  Pacritinib (PAC), a multi-kinase inhibitor with specificity for JAK2, FLT3, and IRAK1 but sparing JAK1, has demonstrated clinical activity in myelofibrosis with minimal myelosuppression.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29562644",
    "http://www.ncbi.nlm.nih.gov/pubmed/29650801",
    "http://www.ncbi.nlm.nih.gov/pubmed/29522138",
    "http://www.ncbi.nlm.nih.gov/pubmed/26288713",
    "http://www.ncbi.nlm.nih.gov/pubmed/27226728",
    "http://www.ncbi.nlm.nih.gov/pubmed/26367195",
    "http://www.ncbi.nlm.nih.gov/pubmed/25762180",
    "http://www.ncbi.nlm.nih.gov/pubmed/30001163",
    "http://www.ncbi.nlm.nih.gov/pubmed/28441920",
    "http://www.ncbi.nlm.nih.gov/pubmed/29616317",
    "http://www.ncbi.nlm.nih.gov/pubmed/26389774",
    "http://www.ncbi.nlm.nih.gov/pubmed/27931243",
    "http://www.ncbi.nlm.nih.gov/pubmed/29235894",
    "http://www.ncbi.nlm.nih.gov/pubmed/24746271",
    "http://www.ncbi.nlm.nih.gov/pubmed/29785143",
    "http://www.ncbi.nlm.nih.gov/pubmed/28336242"
  ],
  "snippets": [
    {
      "text": "Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29235894",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Pacritinib, a dual JAK2 and FLT3 inhibitor which also inhibits IRAK1, has demonstrated the ability to favorably impact MF-associated splenomegaly and symptom burden, while having limited myelosuppression with manageable gastrointestinal toxicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29235894",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Other JAKis, such as fedratinib and pacritinib, proved to be useful in MF. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29650801",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusions and Relevance: In patients with myelofibrosis and thrombocytopenia, including those with prior anti-JAK therapy, pacritinib twice daily was more effective than BAT, including ruxolitinib, for reducing splenomegaly and symptoms.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29522138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Developments of JAK inhibitors, such as ruxolitinib, pacritinib, momelotinib, and febratinib enabled the effective management in MF patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29562644",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Pacritinib (PAC), a multi-kinase inhibitor with specificity for JAK2, FLT3, and IRAK1 but sparing JAK1, has demonstrated clinical activity in MF with minimal myelosuppression. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29616317",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pacritinib could be a treatment option for patients with myelofibrosis, including those with baseline cytopenias for whom options are particularly limited.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28336242",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusions and Relevance\nIn patients with myelofibrosis and thrombocytopenia, including those with prior anti-JAK therapy, pacritinib twice daily was more effective than BAT, including ruxolitinib, for reducing splenomegaly and symptoms.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29522138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert commentary: Pacritinib has demonstrated promising results in patients with myelofibrosis and thrombocytopenia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30001163",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pacritinib, a dual JAK2 and FLT3 inhibitor, improves disease-related symptoms and signs with manageable gastrointestinal toxicity in patients with myelofibrosis with splenomegaly and high-risk features, without causing overt myelosuppression, and therefore may provide an important treatment option for a range of patients with myelofibrosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26367195",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pacritinib is an active agent in patients with MF, offering a potential treatment option for patients with preexisting anemia and thrombocytopenia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25762180",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pacritinib (PAC), a multi-kinase inhibitor with specificity for JAK2, FLT3, and IRAK1 but sparing JAK1, has demonstrated clinical activity in MF with minimal myelosuppression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29616317",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article examines the role of JAK2 and FLT3 signaling in myelofibrosis and provides an overview of the clinical development of pacritinib as a new therapy for myelofibrosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26367195",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pacritinib appears to be an effective agent for the control of MF-related symptoms and splenomegaly with potentially fewer haematological side-effects when compared with ruxolitinib and seems a particularly promising agent for anaemic and thrombocytopenic patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26389774",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert commentary: Pacritinib has demonstrated promising results in patients with myelofibrosis and thrombocytopenia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30001163",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}